Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure 
Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand 
Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report 
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Tesla Launches New Model Y Variant in the US Starting at $41,990 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate 
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
Instagram Outage Disrupts Thousands of U.S. Users 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
MALAKOFF, France, Aug. 22, 2017 -- THERACLION (Alternext, FR0010120402 - ALTHE), a company specialized in leading-edge medical equipment for echotherapy, today announced that it will host a conference call and webcast to discuss the recently FDA-authorized clinical trial combining the checkpoint inhibitor, pembrolizumab, with Theraclion’s echotherapy (also known as High Intensity Focused Ultrasound, HIFU) in women with metastatic breast cancer. David Brenin, M.D., a co-lead investigator of the trial will describe the clinical trial.
Event: Theraclion Echotherapy + Immuno-Oncology Combination Clinical Trial
Date: Thursday, September 7, 2017
Time: 11 a.m. EDT
The dial-in numbers for the call are +1-877-718-5107 (United States) and +1-719-325-4917 (International). The conference ID number is 9476148. A live webcast of the conference call will be available on the investor relations page of the Theraclion corporate website at www.theraclion.com. The webcast will also be archived for one year on the investor relations page of the company’s website.
David Brenin, M.D., FACS, is chief of breast surgery, co-director of both the University of Virginia (UVA) Breast Care Program and the High-Risk Breast and Ovarian Cancer Clinic and is an associate professor of surgery at UVA’s School of Medicine. His clinical practice specializes in the treatment of breast cancer, and benign diseases of the breast. Dr. Brenin is a fellowship trained breast surgeon and is an expert on surgical procedures involving the breast including lumpectomy, sentinel node biopsy, axillary dissection, nipple sparing mastectomy and IORT. His primary research interests include focused ultrasound ablation of breast tumors and immunotherapy.
About Theraclion
Theraclion is a French company specializing in high-tech medical equipment using therapeutic ultrasound. Drawing on leading-edge technologies, Theraclion has designed and manufactured an innovative solution for echotherapy, the Echopulse®, allowing non-invasive tumor treatment through ultrasound-guided high-intensity focused ultrasound. Theraclion is ISO 13485 certified and has received the CE mark for non-invasive ablation of breast fibroadenomas and thyroid nodules. Based in Malakoff, near Paris, France Theraclion has brought together a team of 34 people, 50% of whom are dedicated to R&D and clinical trials. For more information, please visit Theraclion’s website: www.theraclion.com.
Theraclion is listed on Alternext Paris
PEA-PME Eligible
Mnemonic: ALTHE - ISIN Code: FR0010120402
Contacts: Theraclion David Caumartin CEO Tel.: +33 (0)1 55 48 90 70 [email protected] Kalima Press Relations Florence Calba Tel.: + 33 (0)1 44 90 82 54 [email protected] The Ruth Group (U.S.) Investor Relations / Public Relations Robert Flamm / Kirsten Thomas +1 646-536-7017 / +1 508-280-6592 [email protected] / [email protected]
